These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 20594801)

  • 21. Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer.
    Blick SK; Wagstaff AJ
    Drugs; 2006; 66(18):2387-93; discussion 2394-5. PubMed ID: 17181383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fentanyl buccal tablet (Fentora) for breakthrough pain.
    Med Lett Drugs Ther; 2007 Sep; 49(1270):78-9. PubMed ID: 17878889
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
    Tawfik MO; Bryuzgin V; Kourteva G;
    Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fentanyl buccal tablet for breakthrough cancer pain: why titrate?
    Kleeberg UR; Filbet M; Zeppetella G
    Pain Pract; 2011; 11(2):185-90. PubMed ID: 20807349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.
    Mercadante S
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):9-13. PubMed ID: 25359295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain.
    Passik SD; Narayana A; Yang R
    Pain Med; 2014 Aug; 15(8):1365-72. PubMed ID: 24666664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fentanyl effervescent buccal tablets: new formulation. For cancer patients with breakthrough pain: a second buccal formulation with minimal evaluation.
    Prescrire Int; 2009 Oct; 18(103):205. PubMed ID: 19882786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation.
    Takigawa C; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
    Jpn J Clin Oncol; 2015 Jan; 45(1):67-74. PubMed ID: 25381384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study.
    Lennernäs B; Frank-Lissbrant I; Lennernäs H; Kälkner KM; Derrick R; Howell J
    Palliat Med; 2010 Apr; 24(3):286-93. PubMed ID: 20015921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral transmucosal fentanyl: new preparation. For breakthrough cancer pain when morphine fails.
    Prescrire Int; 2002 Aug; 11(60):106-7. PubMed ID: 12199262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain.
    Zeppetella G; Messina J; Xie F; Slatkin NE
    Pain Pract; 2010; 10(4):287-93. PubMed ID: 20230447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Individual aspects of the quality of life of patients with chronic pain. Observational study of treatment with fentanyl-TTS].
    Zimmermann M; Waap I
    MMW Fortschr Med; 2005 Apr; 147 Suppl 1():33-40. PubMed ID: 16739370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review.
    Darwish M; Xie F
    Pain Pract; 2012 Apr; 12(4):307-14. PubMed ID: 21831253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fentanyl buccal tablet: rapid relief from breakthrough pain.
    Taylor DR
    Expert Opin Pharmacother; 2007 Dec; 8(17):3043-51. PubMed ID: 18001263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
    Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
    Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain.
    Otis J; Rothman M
    Curr Med Res Opin; 2006 Aug; 22(8):1493-501. PubMed ID: 16870074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent development in therapeutics for breakthrough pain.
    Davis MP
    Expert Rev Neurother; 2010 May; 10(5):757-73. PubMed ID: 20420495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.